<img src="https://secure.leadforensics.com/63407.png" originalAttribute="src" originalPath="https://secure.leadforensics.com/63407.png" style="display:none;" /> Immunizations
KAFP Instant News
Print
Immunizations
Posted on Friday, September 1, 2017

CDC publishes ACIP 2017–18 influenza
vaccination recommendations

IAC Express

CDC published Prevention and Control of Seasonal Influenza with
Vaccines: Recommendations of the Advisory Committee on Immunization
Practices—United States, 2017–18 Influenza Season"
in the August 25
MMWR Recommendations and Reports. The first three paragraphs of the
Summary section are reprinted below.

This report updates the 2016–17 recommendations of the Advisory Committee
on Immunization Practices (ACIP) regarding the use of seasonal influenza
vaccines (MMWR Recomm Rep 2016;65[No. RR-5]). Routine annual influenza
vaccination is recommended for all persons aged ≥6 months who do not have
contraindications. A licensed, recommended, and age-appropriate vaccine 
should be used.


For the 2017–18 season, quadrivalent and trivalent influenza vaccines will
be available. Inactivated influenza vaccines (IIVs) will be available in trivalent
(IIV3) and quadrivalent (IIV4) formulations. Recombinant influenza vaccine
(RIV) will be available in trivalent (RIV3) and quadrivalent (RIV4) formulations.
Live attenuated influenza vaccine (LAIV4) is not recommended for use during
the 2017–18 season due to concerns about its effectiveness against
(H1N1)pdm09 viruses during the 2013–14 and 2015–16 seasons.
Recommendations for different vaccine types and specific populations are
discussed. No preferential recommendation is made for one influenza vaccine
product over another for persons for whom more than one licensed,
recommended product is available.


Updates to the recommendations described in this report reflect discussions
during public meetings of ACIP held on October 20, 2016; February 22, 2017;
and June 21, 2017.
New and updated information in this report includes the following:

  • Vaccine viruses included in the 2017–18 U.S. trivalent influenza
    vaccines will be an A/Michigan/45/2015 (H1N1)pdm09–like virus,
    an A/Hong Kong/4801/2014 (H3N2)-like virus, and a B/Brisbane/
    60/2008–like virus (Victoria lineage). Quadrivalent influenza vaccines
    will contain these three viruses and an additional influenza B vaccine
    virus, a B/Phuket/3073/2013–like virus (Yamagata lineage).
  • Information on recent licensures and labelling changes is discussed,
    including licensure of Afluria Quadrivalent (IIV4; Seqirus, Parkville,
    Victoria, Australia); Flublok Quadrivalent (RIV4; Protein Sciences,
    Meriden, Connecticut); and expansion of the age indication for
    FluLaval Quadrivalent (IIV4; ID Biomedical Corporation of Quebec, Quebec
    City, Quebec, Canada), previously licensed for ≥3 years, to ≥6 months.
  • Pregnant women may receive any licensed, recommended,
    age-appropriate influenza vaccine.
  • Afluria (IIV3; Seqirus, Parkville, Victoria, Australia) may be used for persons
    aged ≥5 years, consistent with Food and Drug Administration
    approved labeling.
  • FluMist Quadrivalent (LAIV4; MedImmune, Gaithersburg, Maryland)
    should not be used during the 2017–18 season due to concerns about
    effectiveness against influenza A(H1N1)pdm09 viruses in the United States
    during the 2013–14 and 2015–16 influenza seasons.
Read the full report here.